Atara Biotherapeutics, Inc. (ATRA)
NASDAQ: ATRA · Real-Time Price · USD
14.33
+0.13 (0.92%)
At close: Dec 5, 2025, 4:00 PM EST
14.77
+0.44 (3.07%)
After-hours: Dec 5, 2025, 6:37 PM EST
Atara Biotherapeutics Employees
Atara Biotherapeutics had 153 employees as of December 31, 2024. The number of employees decreased by 72 or -32.00% compared to the previous year.
Employees
153
Change (1Y)
-72
Growth (1Y)
-32.00%
Revenue / Employee
$993,007
Profits / Employee
$152,948
Market Cap
103.32M
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ATRA News
- 23 days ago - Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress - Business Wire
- 4 weeks ago - Pierre Fabre Pharmaceuticals Announces Transfer from Atara Biotherapeutics of the Biologics License Application (BLA) for Tabelecleucel as Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) - PRNewsWire
- 2 months ago - 4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals - Benzinga
- 3 months ago - Atara Biotherapeutics Announces Changes to Its Board of Directors - Business Wire
- 4 months ago - Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress - Business Wire
- 4 months ago - Pierre Fabre Pharmaceuticals Inc. Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Tabelecleucel for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) - PRNewsWire
- 4 months ago - Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease - Business Wire
- 5 months ago - Perre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc. - PRNewsWire